GA
UTHR icon

GraniteShares Advisors’s United Therapeutics UTHR Stock Holding History

GraniteShares Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Buy
+770
New +$434K 0.27% 81
2025
Q4 		– Sell
-1,435
Closed -$602K – 115
2025
Q3 		$602K Buy
1,435
+108
+8% +$36.3K 0.35% 74
2025
Q2 		$381K Buy
1,327
+52
+4% +$15.5K 0.23% 90
2025
Q1 		$393K Buy
1,275
+21
+2% +$7.2K 0.25% 84
2024
Q4 		$442K Buy
+1,254
New +$461K 0.28% 85

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

GraniteShares Advisors's UTHR Position: Q2 2026 in Review

GraniteShares Advisors opened a new position in United Therapeutics (UTHR) in Q2 2026: 770 shares worth $417K. The stake represents 0.27% of the portfolio and ranks #81 among its holdings. This is a return to the name: GraniteShares Advisors previously reported a position in UTHR as recently as Q3 2025.

GraniteShares Advisors first reported a position in UTHR in Q4 2024 and has held it in 5 quarters since. The position peaked at $602K in Q3 2025. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • GraniteShares Advisors held 770 shares of United Therapeutics worth $417K as of Q2 2026.
  • United Therapeutics was a new GraniteShares Advisors position in Q2 2026.
  • United Therapeutics made up 0.27% of GraniteShares Advisors's portfolio in Q2 2026, its #81 holding.
  • GraniteShares Advisors first reported a position in United Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • GraniteShares Advisors's United Therapeutics position peaked at $602K in Q3 2025.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on GraniteShares Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.